Denali is based in South San Francisco. Denali Building Supply was established on March 18th of this year and has made great strides to help customers within the community during the recent pandemic. “We are also enthusiastic about advancing two new molecules toward the clinic, DNL343 for ALS and other neurodegenerative diseases and DNL310 for Hunter syndrome, which is also expected to generate proof-of-concept in humans for our Transport Vehicle blood-brain barrier delivery platform.”DNL201 and DNL151 (LRRK2 inhibitors) for Parkinson’s diseasePhase 1b results with DNL201 in patients with Parkinson’s disease met all biomarker goals by demonstrating greater than 50 percent inhibition of pS935 LRRK2 and pRAB10 in blood for both doses tested and improvement of the lysosomal biomarker BMP (22:6-bis-monoacylglycero-phosphate) by 20 percent and 60 percent in urine at the low and high dose, respectively.DNL201 was generally well tolerated at the low dose and the majority of subjects experienced either no or mild adverse events (“AEs”). The AP news staff was not involved in its creation.Connect with the definitive source for global and local news Furthermore, a CTA for a Phase 1 first-in-human healthy volunteer study of EIF2B activator DNL343, intended for the treatment of ALS and other neurodegenerative diseases, has been approved. This is Denali’s third small molecule program engineered to cross the BBB to advance to clinical testing.“We are pleased with the continued progress across our pipeline, including a significant step forward for our LRRK2 program with encouraging clinical data in patients and healthy subjects for two molecules,” said Ryan Watts, Ph.D., CEO. The forward-looking statements in this press release are based on information available to Denali as of the date hereof. “The launch of our Engage Parkinson’s website is intended to strengthen our engagement and interactions with the Parkinson’s disease patient community. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development through biomarkers that demonstrate target engagement and select patients. For additional information, please visit Cautionary Note Regarding Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this press release are based on information available to Denali as of the date hereof. All treatment-related AEs were manageable and reversible.Phase 1 results with DNL151 in more than 150 healthy volunteers also met all safety and biomarker goals. Denali is based in South San Francisco. or. The AP news staff was not involved in its creation.Press release content from Globe Newswire. Press Release. There was one SAE considered unrelated to drug. The forward-looking statements in this press release are based on information available to Denali as of the date hereof. Mutations in EIF2B are genetically linked to neurodegenerative diseases. Activation of EIF2B with DNL343 is expected to restore protein synthesis and reduce formation of stress granules, which are commonly associated with disease pathology in ALS and Alzheimer’s disease. Contacts: Lizzie Hyland(646) 495-2706 lhyland@gpg.com.

Denali disclaims any obligation to update any forward-looking statements, except as required by law. Date: Thursday, July 23, 2020 Contact: Interior_Press@ios.doi.gov WASHINGTON – Today, the Department of the Interior announced decisions for the Alaska Liquified Natural Gas (Alaska LNG) Pipeline Project, approving the issuance of rights-of-way permits across federal lands managed by the Bureau of Land Management (BLM) and National Park Service (NPS). The presentation will also be accessible by webcast through Denali’s website at Denali is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the BBB for neurodegenerative diseases. The forward-looking statements in this press release are based on information available to Denali as of the date hereof. Denali Therapeutics (NASDAQ:DNLI): Q2 GAAP EPS of -$0.56 beats by $0.04.Revenue of $5.85M (+39.3% Y/Y) beats by $1.62M.Press Release For additional information, please visit www.denalitherapeutics.com.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Denali disclaims any obligation to update any forward-looking statements, except as required by law. “We look forward to further exploring the full therapeutic potential of LRRK2 inhibitors in future clinical studies.”Denali submitted an IND in late December 2019 for DNL310, or ETV:IDS, a recombinant form of the iduronate 2-sulfatase (“IDS”) enzyme engineered to cross the BBB using Denali’s proprietary Enzyme Transport Vehicle technology.